Core Insights - Altamira Gold Corp. has discovered a new high-ranking gold target named Guillermo within the Cajueiro district, with surface grab samples returning 39g/t gold, indicating significant mineralization potential [2][3][5]. Exploration and Discovery - The Guillermo target is located 2.5 km northeast of the Central Resource area in the Cajueiro district, identified through geological mapping, soil sampling, and trenching [4][7]. - The gold-in-soil anomaly at Guillermo is open to the east and is surrounded by historic placer gold workings, suggesting a promising exploration area [4][12]. - The discovery of Guillermo increases the number of new gold targets in the region to three, alongside Mombaque and Espirro, with only the Maria Bonita target having been drilled so far [6][10]. Geological and Resource Information - The Cajueiro project has current NI 43-101 resources of 5.66 million tonnes at 1.02 g/t gold, totaling 185,000 ounces in the Indicated Resource category, and 12.66 million tonnes at 1.26 g/t gold, totaling 515,000 ounces in the Inferred Resource category [9][20]. - Reconnaissance drilling at the Maria Bonita target has yielded initial results of up to 146m at 1g/t gold, marking it as the first gold porphyry discovery in the Cajueiro area [10]. Future Exploration Plans - The company is conducting further exploration at the Guillermo target, including drone magnetics to refine target definitions and prepare for potential drill testing [18]. - The combination of unexplained alluvial gold sources, hydrothermally altered volcanics, and high-grade gold in outcrop at Guillermo presents a significant opportunity for future exploration [18].

Core Insights - SeaStar Medical Holding Corporation estimates a U.S. total addressable market for its Selective Cytopheretic Device (SCD) in five clinical indications to be between $25 billion and $33 billion, pending FDA approvals [1][2]. Market Overview - The estimated annual U.S. patient populations and total addressable markets for the five clinical indications are as follows: - Adult Acute Kidney Injury (AKI): 210,000 patients, market size of $4,700 million to $6,300 million, clinical trial costs of $154 million [2] - Cardiorenal Syndrome without LVAD: 580,000 patients, market size of $13,100 million to $17,400 million, clinical trial costs of $5 million [2] - Adult Acute Respiratory Distress Syndrome (ARDS): 200,000 patients, market size of $4,500 million to $6,000 million, clinical trial costs of $10 million [2] - Adult Hepatorenal Syndrome: 50,000 patients, market size of $1,100 million to $1,500 million, clinical trial costs of $4 million [2] - Cardiorenal Syndrome with LVAD: 60,000 patients, market size of $1,400 million to $1,800 million, clinical trial costs of $4 million [2] Regulatory Milestones - The SCD has received FDA Breakthrough Device Designation for three indications: adult AKI, hepatorenal syndrome, and cardiorenal syndrome with LVAD, which facilitates faster development and priority review by the FDA [2][6]. - The company has achieved a significant regulatory milestone by securing approval for the SCD-Pediatric, branded as QUELIMMUNE, for treating critically ill children with AKI and sepsis [2][7]. Clinical Trials - The NEUTRALIZE-AKI pivotal trial aims to enroll up to 200 adults, with 69 subjects already enrolled. The primary endpoint is a composite of 90-day mortality or dialysis dependency [8]. - Secondary endpoints include mortality at 28 days, ICU-free days in the first 28 days, major adverse kidney events at Day 90, and dialysis dependency at one year [8]. Company Overview - SeaStar Medical is a commercial-stage medical technology company focused on developing cell-directed extracorporeal therapies to mitigate excessive inflammation in critically ill patients [9].

Dublin, Dec. 11, 2024 (GLOBE NEWSWIRE) -- The "FcRn Inhibitor Market Size, Target Population, Competitive Landscape & Market Forecast - 2034" report has been added to ResearchAndMarkets.com's offering. This report delivers an in-depth understanding of the FcRn inhibitor, historical and Competitive Landscape as well as the FcRn inhibitors' market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.The report provides current treatment practices, emerging dr ...

Core Points - Bonterra Resources Inc. announced additional assay results from the Moss target and the restart of drilling by Gold Fields at the Phoenix JV project, which is under a joint venture agreement with Osisko Mining Inc. [2][15] - Gold Fields can acquire up to a 70% interest in the project by spending C$30 million, with a minimum annual commitment of C$10 million over three years [2][15] - Recent drilling at the Moss target has revealed high-grade mineralization, with significant results including 38.33 g/t Au over 1.1 m and 7.37 g/t Au over 4.2 m [4][5] Additional Assay Results - Over 60,000 meters have been drilled at the Moss target, with approximately C$16 million spent this year by Osisko under the joint venture agreement [4] - Notable assay results include: - 6.23 g/t Au over 2.8 m, including 18.1 g/t Au over 0.9 m in hole OSK-PHX-24-112 - 12.3 g/t Au over 0.5 m and 3.97 g/t Au over 3.4 m in hole OSK-PHX-24-073 - 7.50 g/t Au over 0.9 m, including 20.9 g/t Au over 0.3 m in hole OSK-PHX-24-106 [5] Drilling Plans by Gold Fields - Gold Fields is planning a potential 20,000 meters drilling program, with three to four drill rigs mobilized primarily along the Barry Shear Zone [6][7] - The program will target several areas, including the Gladiator SW and NE/Titan targets, which are adjacent to the Gladiator deposit containing 0.4 million ounces of Measured and Indicated Mineral resources and 1.0 million ounces of Inferred Mineral resources [7]

If you want full access to all our reports, data and investing ideas, join The Aerospace Forum , the #1 aerospace, defense and airline investment research service on Seeking Alpha, with access to evoX Data Analytics, our in-house developed data analytics platform.Airbus ( OTCPK:EADSF ) ( OTCPK:EADSY ) and Boeing ( BA ) have had significant challenges in raising production rates on their commercial airplane programs. While different in nature, the result is the same: Airlines are suffering fromDhierin runs t ...

Core Viewpoint - Target and Walmart are leading retail stocks that offer potential for long-term growth and dividend income, with Walmart currently outperforming Target in stock performance [1][2]. Dividend Performance - Walmart's current dividend yield is approximately 1%, below the S&P 500 average of 1.2%, while Target offers a higher yield of 3.4% [3][4]. - To receive a $1,000 dividend from Walmart, an investment of around $100,000 is needed, whereas less than $30,000 is required for the same dividend from Target [4]. Dividend Growth - Target has increased its dividend by nearly 2% this year, marking the 53rd consecutive year of dividend increases, while Walmart raised its dividend by 9% in February, achieving 51 consecutive years of increases [6][7]. - Over the past decade, Target has doubled its dividend, significantly outpacing Walmart's 27.04% increase [8]. Payout Ratios - Both companies maintain payout ratios below 50%, with Walmart at 33.23% and Target at 46.70%, indicating sustainable dividend payments [9][11]. - A lower payout ratio for Walmart suggests a preference for retaining earnings for growth strategies rather than distributing them to shareholders [10]. Investment Considerations - Target's current struggles due to weak demand for discretionary products may improve with better economic conditions, presenting a potential value opportunity compared to Walmart's higher valuation [12]. - For long-term dividend income investors, Target may represent a more attractive investment option than Walmart at this time [13].

Target has failed to persuade a judge in Florida to dismiss a lawsuit that accused the retailer of deceiving shareholders after its sales of LGBTQ-themed merchandise for Pride Month sparked a backlash and a customer boycott.US District Judge John Badalamenti in Fort Myers ruled that the plaintiffs had presented enough information for now to pursue claims that Target misled investors about its efforts to guard against social and political risks.The lawsuit from investor Brian Craig claims that Target’s board ...

Since running into $2,700 in October, gold prices have cooled off, consolidating below this mark, though still elevated compared to the last 12 months. Gold traders have joined the the safe-haven asset in pulling back, but if past is precedent, one industry heavyweight could be ready to rally.Newmont Corporation (NYSE:NEM) is one of the top stocks on the SPX to own in December going back a decade. Per Schaeffer's Senior Quantitative Analyst Rocky White, the miner averages a 4.4% return in December, and has ...

Shares of Target (TGT 0.56%) were sliding last month, as a broader recovery in the stock market wasn't enough to overcome another disappointing earnings report from the retail giant.Target missed estimates on the top and bottom lines and cut its guidance. It's still struggling with weak consumer discretionary spending and challenges with inventory management.According to data from S&P Global Market Intelligence, the stock finished the month down 12%. Target was trading similarly to the S&P 500 for most of t ...

Gold miners, as measured by the VanEck Vectors Gold Miners ETF ( GDX ), have pared their year-to-date gain. The ETF is up 21%, dividends included, so far in 2024, underperforming the SPDR Gold Trust ETF ( GLD ) byFreelance Financial Writer | Investments | Markets | Personal Finance | RetirementI create written content used in various formats including articles, blogs, emails, and social media for financial advisors and investment firms in a cost-efficient way. My passion is putting a narrative to financial ...